Press Release

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com

CORCEPT THERAPEUTICS APPOINTS DAVID L. MAHONEY TO BOARD OF DIRECTORS

MENLO PARK, Calif., (July 26, 2004) - Corcept Therapeutics announced today that David L. Mahoney has been appointed to the Company's Board of Directors effective immediately.

"We are fortunate to have an individual of David's caliber, who brings significant healthcare industry, financial and managerial experience to Corcept," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "His expertise in the managed distribution of ethical pharmaceuticals, strategy and corporate development will make him an invaluable addition as we plan and implement the commercialization of our products."

Mr. Mahoney served as co-CEO of McKesson HBOC, Inc. and as CEO of iMcKesson LLC from July 1999 to February 2001. He joined McKesson in 1990 as Vice President for Strategic Planning, and is credited with developing innovative business strategies to grow the PCS Health System subsidiary, leading to the sale of PCS to Eli Lilly & Co. He had overall responsibility for McKesson's strategic relations with pharmaceutical and biotechnology companies and was responsible for the establishment of the Pharmaceutical Partners Group at McKesson which provides product development, sales and marketing support to the pharmaceutical and biotechnology industry. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company from 1981 to 1990. He also serves on the Board of Directors of Symantec Corporation, Live Oak School and KQED. Mr. Mahoney has a bachelor's degree from Princeton University and a master's of business administration from Harvard University.

About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX™, is currently in Phase III clinical trials for the treatment of the psychotic features of psychotic major depression. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. Corcept is also conducting a clinical trial to evaluate the safety and efficacy of our product in improving cognition in patients with mild to moderate Alzheimer's disease. For additional information about the company, please visit www.corcept.com.